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Advances in immunoglobulin (Ig) sequencing technology are leading to new
perspectives on immune system dynamics. Much research in this nascent field
has focused on resolving immune responses to viral infection. However, the
dynamics of B-cell diversity in early HIV infection, and in response to anti-
retroviral therapy, are still poorly understood. Here, we investigate these
dynamics through bulk Ig sequencing of samples collected over 2 years
from a group of eight HIV-1 infected patients, five of whom received anti-
retroviral therapy during the first half of the study period. We applied
previously publishedmethods for visualizing and quantifying B-cell sequence
diversity, including the Gini index, and compared their efficacy to alternative
measures. While we found significantly greater clonal structure in HIV-
infected patients versus healthy controls, within HIV patients, we observed
no significant relationships between statistics of B-cell clonal expansion and
clinical variables such as viral load and CD4þ count. Although there are
many potential explanations for this, we suggest that important factors include
poor sampling resolution and complex B-cell dynamics that are difficult to
summarize using simple summary statistics. Importantly, we find a significant
association between observedGini indices and sequencing read depth, andwe
conclude that more robust analytical methods and a closer integration of
experimental and theoretical work is needed to further our understanding
of B-cell repertoire diversity during viral infection.1. Introduction
The recent application of high-throughput sequencing technology to immunology,
and to the characterization of B-cell and T-cell receptor diversity in particular, has
the potential to reveal immune system dynamics in unprecedented detail [1–3].
This work has led to advances in our understanding of antibody dynamics after
vaccination [4,5], the effects of aging and infection on the B-cell repertoire [6],
the development of B-cell cancers [7,8] and the onset of autoimmune disorders
such as multiple sclerosis [9]. Many of these studies have taken an ‘antibodyome’
perspective to viral infection, in which the immune response to infection is inves-
tigated by the bulk sequencing from patient samples of the antigen-binding
regions of B-cell immunoglobulin (Ig) genes. These sequences are then analysed
to explore how the antibody repertoire changes in response to perturbation arising
fromviral evolution and vaccination. This approachhas been applied, for example,
to influenza virus [5,10], varicella-zoster virus [11] and dengue virus [12].
Some of the most notable findings in this field have come from detailed inves-
tigation of the interactions between the humoral immune system and HIV-1
infection. Much of this work has focused on observing and understanding the
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order to aid the development of preventative HIV-1 vaccines
[13]. Interestingly, bNAb precursors may be preferred in vac-
cine design over observed bNAbs because they may have a
wider binding profile, and the sequences of such precursors
can be inferred using methods of phylogenetic ancestral
sequence reconstruction [14]. This requires an understanding
of the diversity and dynamics of B-cell clones during infection,
and significant strides have been made, both in tracking the
coevolution of B-cell and viral lineages, [15–17] and in finding
potential bNAb precursors using phylogenetic methods [14].
Despite these advances, more general trends in B-cell diver-
sity and clonal dynamics during HIV-1 infection are still poorly
understood, particularly during early infection. While some
studies have contrasted the plasmablast, naive and memory
B-cell content between early and chronic infections [18], the
diversity of patient ‘antibodyomes’ has not yet been character-
ized, either in comparison to healthy controls or through time in
individuals that have recently seroconverted. Although early
anti-retroviral therapy (ART) has been shown to have a signifi-
cant effect on viral divergence (e.g. [19]), the corresponding
effect on B-cell clonal diversity under ART is unknown. While
it may be expected that B-cell populations in HIVþ individuals
are more clonal than in uninfected individuals, and that the
degree of B-cell clonal relatedness is related to the size of
the concurrent viral population, these associations have not
been explicitly tested.
Most previous studies that investigated the repertoire of
B-cell receptor (BCR) diversity in peripheral blood (as opposed
to those that focused on specific clonal lineages, e.g. [15]) have
typically used non-phylogenetic approaches to summarize
B-cell diversity. One successful approach has been to use
single-linkage clustering to group sequences into clusters (or
clones), and then to infer clonal expansions bymeasuring prop-
erties of the size distribution of clones using entropy scores,
such as the Gini index [8]. Others studies have used alternative
statistics, including mean clone size, the number of unique
IgHV-D-J allele combinations, and genetic distances between
IgV segment sequences and their respective germline homo-
logues (e.g. [7]). Both sets of approaches have shown promise
in studying B-cell cancers, which result from significant
clonal expansions of usually one BCR lineage [20], but it
is unknown if a similar approach will be informative when
studying immune responses to HIV infection.
To better understand B-cell repertoire dynamics during
early HIV infection and the degree to which it is modulated
by ART, we used deep-sequencing to capture the diversity
of Ig heavy-chain sequences from eight HIV patients enrolled
in the short pulse anti-retroviral therapy at seroconversion
(SPARTAC) trial [21]. This is, to our knowledge, the first
time high-throughput BCR sequencing has been applied to
studying general B-cell clonal diversity during ART and
early HIV infection. Patients were enrolled an estimated
12–95 days after seroconversion, and were sampled at up
to eight time points over approximately 2 years. At each
time point, B-cell repertoire sequencing was performed and
both viral load and CD4þ T-cell counts were measured.
Three patients were untreated, while five received ART for
the first 48 weeks of the study only. This study design not
only allows us to track individual B-cell clones during early
infection, but also to test for associations between the
dynamics of B-cell sequence diversity and clinical variables,
including treatment status.For each patient and each time point, we used a high-
throughput Illumina MiSeq platform to obtain paired-end
reads from Ig heavy-chain sequences that represent the mixture
of antibody classes in peripheral blood. Within each patient, we
extended a previous single-linkage clustering approach [8] to
classify sequences into clones and track their relative frequencies
through time.We also explored a number of statistics in order to
quantify BCR sequence diversity from HIV-1 infected patients,
and to compare this diversity to that observed in a cohort of
HIV-negative controls. While some general patterns were
observed, overall we found a high degree of heterogeneity in
B-cell clonal dynamics both among patients and through time.2. Material and methods
(a) HIV patients
Peripheral blood mononuclear cells (PBMCs) were isolated from
eight patients with primary HIV-1 infection recruited from the
SPARTAC study [21]. All had recently seroconverted before
enrolment in the trial (an estimated 12–93 days before enrolment;
median ¼ 56 days). Patients 1–3 were untreated during the study
period. Patients 4–8 received an ART regimen from week 0 to
week 48, after which treatment was suspended. Patients were
sampled between six and eight times over 108 weeks of the
study (all time points are defined as weeks after start of the
study, defined as week 0). All patients were sampled at weeks
4, 16, 24, 52, 60 and 108, whereas four patients were also sampled
at week 0, and six at week 12. To ensure consistency among
patients, and to ensure an equal number of time points during
and after ART, only the former time points were used in analysis.
(b) RT-PCR
RT-PCR reagents were purchased from Invitrogen and primers
(supplied by Sigma Aldrich) are described by Van Dongen
et al. [22] and in electronic supplementary material, table S1.
Reverse transcription (RT) was performed using 500 ng of total
PBMC RNA mixed with 1 ml JH reverse primer (10 mM), 1 ml
dNTPs (0.25 mM) and RNase-free water added to make a total
volume of 11 ml. This was incubated for 5 min at 658C, and
4 ml First strand buffer, 1 ml DTT (0.1 M), 1 ml RNaseOUTTM
Recombinant Ribonuclease Inhibitor and 1 ml SuperScriptTM III
reverse transcriptase (200 units ml21) was added. RT was per-
formed at 508C for 60 min before heat-inactivation at 708C for
15 min. PCR amplification of cDNA (5 ml of the RT product)
was performed with the JH reverse primer and the FR1 forward
primer set pool (0.25 mM each), using 0.5 ml Phusionw High-
Fidelity DNA Polymerase (Finnzymes), 1 ml dNTPs (0.25 mM),
1 ml DTT (0.25 mM), per 50 ml reaction. The following PCR pro-
gramme was used: 3 min at 948C, 35 cycles of 30 s at 948C, 30 s at
608C and 1 min at 728C, with a final extension cycle of 7 min at
728C on an MJ Thermocycler.
(c) Sequencing and reference-based V-D-J assignment
MiSeq libraries were prepared using Illumina protocols and
sequenced by 150 bp paired-ended MiSeq (Illumina). MiSeq
reads were filtered for base quality (median more than 32) using
QUASR (http://sourceforge.net/projects/quasr) [23]. Sequences
were concatenated and a gap inserted between the forward and
reverse reads (average gap length approx. 35 nucleotides; elec-
tronic supplementary material, figure S2). Non-Ig sequences
were removed; only those reads with significant similarity to
reference IgHV and IgHJ genes from the ImMunoGeneTics
(IMGT) database [24] were retained, as determined using BLAST
[25] with E-value thresholds of 1  10210 and 1  102,
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
370:20140241
3
 on August 7, 2015http://rstb.royalsocietypublishing.org/Downloaded from respectively. Primer sequences were then trimmed from the reads,
and sequences retained for analysis only if both primer sequences
were identified and if both forward and reverse sequence lengths
were more than 100 bp. Lastly, a second BLAST analysis was used
to identify the IgHV genes of retained reads. Specifically, BLAST
[25] was used to align reads against known BCR sequences from
the IMGT database [24] (E-value thresholds for IgHV and IgHJ
genes were 10270 and 10220, respectively, due to their different
gene lengths). The combined per-base error rate for the RT-PCR
and sequencing process of the MiSeq platform was 2.06 1024
[8,26]. Sequences and BAM files are available from the European
Nucleotide Archive under study accession no. ERP000572.
(d) Alignment
The data comprised non-overlapping paired-end reads separated
by a gap of variable and unknown length. This necessitated cer-
tain heuristic measures during data processing and the two reads
of each pair were aligned separately to ensure positional hom-
ology. As above, reference IGHV and IGHJ segments were
obtained from IMGT [24]. Gaps were removed from the reference
sequences, then IGHV sequences were clustered using CD-HIT
[27] with a 95% similarity threshold. Only one sequence was
retained from each cluster, resulting in a smaller set of V seg-
ments. The IHGJ reference sequences were not down-sampled,
however. The first read of each pair was aligned with the closest
matching sequence in the V references through gapless pairwise
alignment. To further optimize the alignment, each read was
matched using only the 50 half of the V segments. Next, the
second read of each pair was pairwise aligned with the closest
sequence in the J references, again using gapless alignment.
Once the first and second reads had been aligned to the V and J
references, respectively, gaps were added 30 of the first read, and
50 of the second read, such that each were 300 nucleotides in
length. The two reads were then concatenated, and excess gaps
were trimmed between each read pair. A graphical representation
of this process is provided in electronic supplementary material,
figure S3. Because we expect sequences from the same clone to
match the same, or highly similar, V and J segments, this process
generates an approximation of the optimal gapless alignment for
sequences from the same clone. Further, the process does not
require sequences to match the same V and J segments in order
to be compared, a requirement that may be problematic when deal-
ing with highly mutated sequences. However, the process may
produce sub-optimal alignments when indel diversity is present
within a clone. A small percentage of reads showed high similarity
between forward and reverse reads (longest common sub-sequence
of 20 bp or greater) and were excluded during this step.
(e) Clonal assignment
Sequences from all time points within each patient were pooled
and assigned to clones using single-linkage agglomerative clus-
tering using the Hamming distance between two sequences [8],
while ignoring gap variation. This latter condition was necessary
because each aligned sequence had an arbitrary gap between its
two reads that resulted from paired-end sequencing, and not
from a natural process of immunological diversification. To
make our results comparable with previous work [8], we also
chose a maximum Hamming distance of unity for clustering
two sequences together into the same clone.
( f ) Measurement of B-cell receptor diversity
The diversity of BCR sequences was qualitatively visualized
using the network approach developed by Bashford-Rogers
et al. [8]. Briefly, each vertex represents a unique BCR sequence,
whose relative size is proportional to the number of sequence
reads identical to the vertex sequence. Edges are then drawnbetween vertices whose sequences differ by at most one nucleo-
tide change. Networks were computed using igraph, as
implemented in R (http://igraph.sourceforge.net; see [8] for
details). Because each clone is shown in proportion to its relative
frequency in the BCR sequence population, these networks pro-
vide an intuitive visualization of the clone size distribution.
Examples of these plots from representatives of the treated and
untreated patient groups are shown in figure 1.
Three sample summary statistics were applied to the BCR
sequences obtained at each time point to summarize their clonal
diversity: (i)mean clone size, (ii) vertexGini index, and (iii) the pro-
portion of reads in ‘large clones’. Each of these three statistics is
described below.
For each time point and each clone, clone size was defined as
the number of reads in the clone at that time point divided by the
total number of reads at that time point. Mean clone size was cal-
culated as the arithmetic mean of this distribution of clone sizes.
Next, the vertex Gini index was used to summarize inequality in
BCR sequence frequency; the index equals unity if all reads have
the same BCR sequence (maximum inequality), and equals zero
if each BCR sequence is equally common (maximum equality).
As defined above, vertex size equals the number of identical
reads with a unique BCR sequence, so the vertex Gini index
was computed directly from the vertex size distribution as
formed using a clustering cut-off of zero. Bashford-Rogers et al.
[8] explored both the vertex and cluster Gini indices, and
found that the former correlated better with clinical parameters
in chronic lymphocytic leukaemia (CLL) patients; hence only
the vertex Gini index is used here.
Clones were classified as ‘large clones’ if they comprised at
least 0.1% of the reads sequenced at any of the time points in
which they were found. We quantified these by calculating the
proportion of reads at each time point that belong to ‘large
clones’. Additionally, we wished to describe changes in the
very upper tail of the clonal size distribution. To do so, we
plotted the sizes of the 20 largest clones as a proportion of the
total number of reads at each time point. These values are for
illustrative purposes only and are not used as sample statistics.
(g) Sub-sampling
Preliminary statistical analysis using ANOVA showed that Gini
index values were significantly associated both with patient iden-
tity ( p ¼ 0.02) and read depth ( p ¼ 0.001). A plot of Gini index
values against read depth for each time point highlights the vari-
ation in read depth among patients (electronic supplementary
material, figure S4). To ensure that comparisons among patients
are reliable and not an artefact of read depth variation, all further
analyses were undertaken on subsamples of the original data.
Specifically, 70 000 sequences were randomly sampled from
each time point in each HIVþ patient (the lowest number of
reads available for a HIVþ patient samplewas 74 861).When com-
paring HIVþ patients with healthy controls (see §2i), then 5000
sequences were randomly sampled from each control and HIVþ
dataset (the lowest number of reads available for a control patient
was 5087). In each case, random sub-sampling of reads was
repeated 10 times. As variance in BCR statistics among these 10
repetitions was very low (less than 1  1024), we only report the
mean values of the 10 sub-sampling repetitions.
(h) Analysis of B-cell receptor diversity
To examine the relationship between BCR sequence diversity and
clinical variables, we compared each of the above BCR statistics
to log(viral load) and CD4þ counts using linear regression.
p-values were adjusted for multiple hypothesis testing using
the Benjamini–Hochberg procedure [28] (as implemented in
the R function p.adjust). To account for possible temporal auto-
correlation within patients, all data points within each patient
(a) (b)
(c) (d)
Figure 1. Network visualization of the diversity of BCR sequences obtained from untreated patient 3 at week 4 (a) and week 108 (b), and from treated patient 4 at
week 4 (c) and week 108 (d ). Each vertex represents a unique sequence, and the size of each vertex is proportional to the number of reads identical to that
sequence. Edges are drawn between vertices that are one nucleotide substitution apart. See §2(f ) for further details.
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significant effect on many variables, such as viral load, we calcu-
lated separate means for values from early time points (weeks
4–24; i.e. during ART for treated patients) and from late time
points (weeks 52–108; when no patients were receiving ART).
These means were calculated by linearly interpolating between
adjacent time points, and then calculating the mean of the result-
ing function between the first and last points (weeks 4 and 24 for
early only, 52 and 108 for late only). ANOVAs were used to
explore how the Gini index and other BCR summary statistic
values vary among patients, time points, treatment status and
read depth. To make linear regression coefficients of each
regression more comparable, all variables besides viral load
and CD4þ count were scaled to a mean of zero and variance of
unity before linear regression and ANOVA analysis.
(i) Comparison with healthy controls
To test whether BCR sequence diversity differs between HIV-
infected and uninfected individuals, we analysed previously
published data from a cohort of six healthy patients [26]. For
each, non-gapped Illumina MiSeq reads were obtained from
PBMCs. See [26] for full details of RNA capture, PCR and
sequencing for the healthy controls. To ensure that these non-
gapped sequences are directly comparable to the gapped
sequences obtained from HIV patients, we only used the first
and last 110 bp of each read, placing a gap of unknown length
between. Because these patients were sequenced at a lower
read depth (5087–8475 reads) than HIVþ patients, all datasets
from healthy controls were randomly sub-sampled (as describedin §2g) to remove any potential bias arising from variable read
depth. Further, when comparing with healthy controls, only
within-time point edges were allowed when identifying clones in
HIV patients (because sequences from only one time point were
available from the control individuals). Differences in BCR diver-
sity statistics between control and HIV-infected individuals were
tested using Wilcoxon tests.3. Results
Figure 1 provides a qualitative visualization of BCR sequence
diversity, and its change between the beginning and end of
the study period (weeks 4 and 108, respectively). The data
shown are from patients 3 and 4 and the plots were computed
using the network approach developed in [8]. For both
patients, the sequences at week 4 are clearlymore clonally clus-
tered compared with those at week 108, although the BCR
diversity for patient 4 (figure 1c) appears more polyclonal
than for patient 3 (figure 1a) at this time. As expected, at neither
time point is the BCR population dominated by a single large
clone, as was often observed in samples from B-cell lymphoma
patients [8]. The plots shown in figure 1 are largely typical of
those observed for other patients.
Full results from all patients are summarized in figures 2
and 3. All patients had seroconverted recently (median ¼ 56
days) before the start of the study (week zero). Patients 1–3
were untreated through the course of the study period
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Figure 2. BCR diversity statistics and viral load values for patients 1–4 (a–d ) over the study period of 108 weeks. Patients 1–3 were untreated, while patient 4
received ART until week 48. Four plots are provided in each panel. The top plot shows viral load, with each point representing a clinical sample. The second plot
shows vertex Gini index values of the BCR sequences obtained at each time point. The third plot shows the proportion of reads at each time point that belong to
‘large’ clones, i.e. those that occupy more than 0.1% of reads at any time point. The bottom plot in each panel shows the proportion of all reads at each time point
that are occupied by the 20 largest clones observed across all time points. Each of the 20 largest clones is represented by a bar of a different colour, and lines
connect bars at adjacent time points that represent the same clone.
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between weeks 0 and 48, after which they were untreated.
BCR sequencing was performed on PMBC samples from
each time point for each patient (yielding 7.4  104 to 1.0 
106 filtered BCR reads per sample). BCR network analysiswas applied to these sequencing datasets to quantify the
clonal architecture of these samples according to Bashford-
Rogers et al. [8]. Four plots are shown for each patient, which
show the change through time in (i) viral load, (ii) the vertex
Gini index of BCR sequences, (iii) the proportion of BCR
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Figure 3. BCR diversity statistics and viral load values for patients 5–8 (a–d) over the study period of 108 weeks. All patients received ART until week 48.
See figure 2 legend for details.
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20 largest clones as a proportion of the total number of reads at
each time point.(a) Untreated patients
All three untreated patients (1–3) showed peak viral loads at or
within four weeks of enrolment, and reduced, but persistentviraemia after 52 weeks corresponding to set point viral load.
Patient 1 had an additional peak in viral load at 24 weeks,
suggesting a superinfection event, and showed a higher viral
load for a longer duration than patients 2 and 3. In all untreated
patients, Gini indexes and the proportion of reads in large
clones were typically higher during the first half of the study,
when viral loads were higher. Hence at these times, a higher
proportion of the BCR sequence population was composed
Table 1. Regression analysis of BCR diversity statistics and clinical variables.
clinical variable BCR diversity statistic correlation adjusted p-valuea
log(viral load), early period mean clone size 20.005 0.99
Gini index 20.13 0.92
proportion of reads in large clones 20.19 0.92
log(viral load), late period mean clone size 0.3 0.92
Gini index 0.37 0.92
proportion of reads in large clones 0.28 0.92
CD4 count, early period mean clone size 20.3 0.92
Gini index 20.43 0.92
proportion of reads in large clones 0.13 0.92
CD4 count, late period mean clone size 20.34 0.92
Gini index 20.47 0.92
proportion of reads in large clones 20.34 0.92
days from seroconversion at week 0, early period mean clone size 20.17 0.92
Gini index 20.19 0.92
proportion of reads in large clones 0.25 0.92
days from seroconversion at week 0, late period mean clone size 20.29 0.92
Gini index 20.36 0.92
proportion of reads in large clones 20.21 0.92
ap-values were adjusted using the Benjamini–Hochberg procedure [28].
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the BCR population (e.g. week 24 in patient 2), that dominance
was not the result of a single dominant clone, but rather
resulted from the concurrent increase in frequency of a large
number of different clones (see bottom plot of each panel in
figure 2). Further, the relative frequencies of individual
clones that were found at high frequencies (colours in bottom
plot of each panel in figure 2) fluctuated through time with
no discernable pattern; in almost all cases, clones were
common at only one time point.
(b) Treated patients
All five treated patients (4–8) showed a rapid decrease in viral
load soon after the start of the study, with counts in weeks
16–24 below 100 copies ml21 (often less than 50, or undetect-
able), coinciding with the period of ART. As expected, viral
load values across all time points were significantly lower in
the treated group than the untreated group (one sided t-test;
p, 0.0001). Patients 5–8 showed a rebound in viral load at
week 52, after the cessation ofART,while the rebound inpatient
4was not as strong and viral loads remained relatively low (less
than 21 000 copies ml21) throughout the study period. In
patients 5–7, viral load decreased in week 60 before stabilizing
at 108 weeks at a similar level to that in untreated patients.
The dynamics of B-cell diversity and clonality in the treated
patients were highly variable. Patient 7 showed a striking pat-
tern after cessation of ART: at week 60, there was a polyclonal
expansion (such that most BCR sequences fell into ‘large’
clones) which remained in week 108. Patient 8 also showed
polyclonal responses and an increase in the proportion of
sequences in large clones at weeks 52 and 108.
BCR diversity dynamics in patient 6 in many ways
resembled those of untreated patients 2 and 3, with a peak
in the prevalence of ‘large clones’ in week 24, and lowclonality in week 108. Patient 4 exhibited high viral load
and clonality at week 4, after which both remained low for
the rest of the study. Patient 5 showed a comparatively
stable level of clonality through time, with the proportion
of sequences in large clones ranging from 0.13 to 0.45. Nota-
bly, patient 5 is the only patient to exhibit a ‘large clone’ that
persisted throughout the study period (red bars in the bottom
panel of figure 3a). Across time points, this persistent clone
occupied between 2.4 and 5.1% of all BCR sequences.
(c) Relationship between clinical variables
and B-cell diversity
We sought to test whether statistics of BCR diversity were
associated with clinical variables, such as viral load, time since
seroconversion and CD4þ cell count (electronic supplementary
material, figure S6). To enable direct comparisons among
patients, all datasets were sub-sampled to exactly 70 000 reads
(see §2g). For each patient, mean values during the early and
late periods were used to account for autocorrelation (see §2h).
As shown in table 1, there was no significant association
between log viral load, CD4þ cell count, or estimated days
since seroconversion with any of the three BCR diversity stat-
istics. In all cases, correlations were non-significant both
before and after correction for multiple hypothesis testing. The
results also remained non-significant when repeated without
adjusting for temporal autocorrelation (i.e. each time point in
each patient counted as an independent data point).
(d) Analysis of B-cell receptor diversity and sub-
sampling
To explore possible sources of variation in the three BCR
statistics, we used ANOVAs to test whether each statistic
was associated with patient identity, week of sampling and
Table 2. ANOVA analysis of BCR diversity statistics.
response factor
mean
square p-valuea
mean clone size patient 0.99 0.63
week 0.49 0.63
treatment 0.6 0.63
Gini index patient 1.7 0.57
week 2.3 0.57
treatment 0.2 0.74
proportion of reads
in large clones
patient 0.48 0.87
week 0.7 0.63
treatment 1.1 0.63
ap-values were adjusted using the Benjamini–Hochberg procedure [28].
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sub-sampled to 70 000 reads. None of these factors explained a
significant proportion of variation in any of the BCR diversity
statistics. Thus, the association between Gini index and patient
identity observed prior to sub-sampling (see §2g and electronic
supplementary material, figure S4) was most likely an artefact
due to variation in read depth among patients.
We also explored the effects of sub-sampling on each of the
three BCR diversity statistics (electronic supplementary
material, figure S7). As might be expected, the ‘proportion of
reads in large clones’ statistic was almost unaffected by sub-
sampling. Although vertex Gini indices were slightly higher
before sub-sampling, this inflation was relatively constant
within patients. Mean clone size was substantially altered by
changes in read depth, justifying our use of sub-sampling
when comparing data from different patients (tables 1 and 2;
figure 4).(e) Comparison with healthy controls
To enable direct comparisons between HIVþ patients and
healthy controls, all datasets were sub-sampled to 5000 reads
(see §2g). As before, values from HIVþ patients were grouped
into two periods, early (weeks 4–24) and late (weeks 52–108)
to avoid temporal autocorrelation. Comparisons of BCR
sequence diversity are shown in figure 4. All three statistics
(mean clone size, Gini index and the proportion of reads in
large clones) were significantly higher in early-period HIVþ
patients than inhealthy controls (p¼ 0.01, 0.02 and0.03, respect-
ively). However, all comparisons between healthy controls and
late-period HIVþ patients were non-significant.4. Discussion
The results presented here demonstrate that BCR sequence
diversity during HIV infection is highly dynamic and hetero-
geneous, both within and among patients. Individual clones
fluctuate substantially in relative frequency, and at no time
point did a single clone dominate the BCR sequence population
in any patient. This suggests an actively evolving antibody
response against HIV, likely due to the high turnover of HIV
genetic diversity within each patient generating novel antigenic
targets (e.g. [29]).We observed significantly greater clonal structure in
HIVþ patients than in uninfected controls during the first
half of the study period, but not during the second half.
This is consistent with a pronounced humoral response to vir-
aemia during early infection. BCR diversity statistics during
the late period were highly variable, suggesting that strong
clonal structure was maintained in some patients but lost or
significantly reduced in others (figure 4). However, when
comparing HIVþ patients, we found no significant associ-
ation between BCR diversity statistics and clinical variables,
such as viral load or CD4þ count, suggesting a highly com-
plex relationship between the adaptive immune system and
viral dynamics. Previous studies have shown highly hetero-
geneous B-cell clonal responses to immune perturbations
such as vaccines over a timescale of weeks [4], so the vari-
ation observed here over a period of approximately 2 years
fits with established findings. Further, once differences in
read depth were accounted for, BCR diversity statistics did
not vary significantly with treatment group, time of sampling
or patient identity.
There are several possible explanations for the heterogen-
eity we observed among HIVþ patients and through time.
The first and simplest explanation is a lack of statistical
power and sampling resolution. With only eight patients,
the power of our study is almost certainly constrained by
small sample size. However, a previous study of B-cell lym-
phoma patients that had a similar sample size and which
used similar analytical techniques was able to establish sig-
nificant associations between BCR clonality and clinical
outcome in CLL patients, likely due to the exceptionally
large B-cell clones generated by this cancer [8]. Another
potentially important factor in our study is the coarseness
of temporal sampling relative to the dynamics of the BCR
sequence population. Each patient was sampled six to eight
times over 2 years, with all time points at least four weeks
apart. Further, the earliest sample taken after ART ended in
the treated group was obtained in week 52. This is potentially
significant because recent studies of vaccine responses that
sampled more intensively have shown that B-cell clones orig-
inating at vaccination tend to expand within the first week
after inoculation and afterwards rapidly contract, with little
persistent expansion after four weeks [4]. Though we might
expect clonal responses to chronic viral infection to be more
persistent than those to vaccination, our sampling scheme
(which was not initially designed with B-cell dynamics in
mind) may not reveal consistent trends in BCR clonality
during HIV infection. Fluctuations that might be associated
with acute infection may be difficult to discern because
(i) some patients were given early treatment, (ii) the time
between seroconversion and the start of the study varied
substantially (12–95 days), and (iii) in one patient there was
evidence of HIV-1 superinfection during the study period.
Further, BCR diversity changes associated with viral rebound
after cessation of ART may not be apparent because patients
were sampled several weeks later.
There are also biological explanations for absence of sig-
nificant relationships between clinical variables and BCR
diversity scores. While the BCR metrics used here were in-
formative when applied to B-cell lymphoma patients, those
patients often exhibited extreme clonality, such that one or
a few B-cell clones comprised the majority of BCR reads [8].
However, the response of the BCR sequence population to
viral infection is likely to be far more subtle and diverse.
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Figure 4. Comparison of three BCR summary statistics among healthy uninfected individuals (blue) and HIV-infected patients. Values from HIVþ patients are
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ing affinity to viral epitopes, BCR diversity will be related not
only to the amount of virus present at the time of sampling,
but also to the antigenic diversity of the virus population,
B-cell longevity and complex ecological dynamics arising
from antigenic cross-reactivity [17]. Further, the dynamical
interaction between viraemia, helper T-cell counts and
T-cell activation of HIV-specific B cells may further obscure
relationships between BCR diversity and other measure-
ments. The network visualizations (figure 1) and BCR
statistics (figures 2 and 3) reported here indicate that the
BCR clone size distribution during early HIV infection is
much less skewed than that observed for B-cell cancers [8],
meaning that HIV-specific clonal expansions may be difficult
to detect from bulk antibody samples without some form
of functional filtering or screening (e.g. antigen-specific cell sort-
ing or isolation of plasmablasts [30]). If so, then further progress
will require very close collaboration between experimental
researchers and theoreticians interested in developing new
analytical approaches. Another process of relevance to studies
of HIV infection is B-cell hypermutation, which has been
shown to generate substantial intra-clonal sequence diversity
and divergence through time [14,15]. If high rates of hypermu-
tation are common, then the conservative clustering algorithm
used here (which only links sequences that differ by one
mutation) may split large and diverse lineages into distinct
groups, thereby reducing its ability to capture BCR dynamics.
Further work is needed to discriminate between inter- and
intra-clonal diversity in a statistically rigorous manner.
Our results are more successful in highlighting the poten-
tial usability and performance of different statistics of BCR
diversity. Although the vertex Gini index proved informative
in prior work [8], we found that it is positively correlated
with sequencing read depth (electronic supplementary
material, figure S4). Application of the Gini index to simple
hypothetical datasets demonstrates why this correlation
may arise (see electronic supplementary material, table S5).
In short, as read depth increases, large clones grow in size
yet more unique singleton reads are also added, thereby
increasing the skew of the clone size distribution, resulting
in a higher Gini index. Bashford-Rogers et al. [8] also explored
the dependence of the Gini index on read depth, via random
sub-sampling of empirical data (electronic supplementarymaterial figure S9 in [8]), although in their study the effect
was small compared with the difference between case and
control patients. In analyses of HIV infection, meaningful
differences in Gini indices are likely more subtle and thus
this statistic may be less effective. One BCR statistic used
here, the ‘proportion of reads in large clones’, showed no sig-
nificant relationship with read depth and was unaffected by
sub-sampling (electronic supplementary material, figure S7)
and is thus worth considering further. Importantly, while
the Gini index attempts to characterize the entire clone size
distribution, and is thus affected by changes in the relative
frequency of very rare variants, statistics such as the pro-
portion of reads in ‘large clones’ focus on the dynamics of
large clones. Substantial theoretical work is needed to under-
stand the sampling properties of BCR diversity statistics and
to develop more powerful alternatives to those used to date.
It is likely that multiple informative statistics will be needed
to adequately summarize BCR repertoires obtained through
bulk sequencing, and may need to consider properties of
the data other than the distribution of clone sizes.
Further methodological challenges face the analysis of BCR
repertoire data obtained through bulk sequencing. A formal,
phylodynamic analysis of BCR sequence data is appealing
because it would allow for model-based inference of par-
ameters such as hypermutation rates and the relative growth
rates of clonal populations. However, because BCR lineages
are created through somatic V(D)J recombination, bulk BCR
sequences do not coalesce to a single common ancestor and
must be separated into distinct lineages before analysis can pro-
ceed. Further, probabilistic models of sequence evolution will
be computationally very demanding when applied to BCR
datasets, some of which—including those used here—contain
millions of unique sequences per patient. If they are developed
in future, phylodynamic methods may be best applied to indi-
vidual B-cell lineages that have been isolated or identified by
experimental, rather than computational, methods.
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